RxDoctor Payments Data

Ginger Fontenot

Family · Lafayette, LANPI 1346693785

Payments from drug & device makers

$6,265in general payments, 2019–2025

Across 257 payments — averaging $24.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$705
  • Amgen$661
  • Insulet Corporation$479
  • AbbVie$397
  • BETA Bionics, Inc.$310
  • Tandem Diabetes Care, Inc.$263
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$6,265100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,265 in reported general payments places this provider in the 90th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$50,489
Medicare patients
301
Services billed
1,641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide99$115,362
MounjaroTirzepatide70$96,203
JardianceEmpagliflozin48$39,311
TrulicityDulaglutide37$38,719
FarxigaDapagliflozin Propanediol27$27,441
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog24$14,888
Tresiba Flextouch U-100Insulin Degludec22$12,982
JanuviaSitagliptin Phosphate16$11,391
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$10,901
Cinacalcet Hcl20$8,958
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$8,929
SynthroidLevothyroxine Sodium82$4,517
Novolog FlexpenInsulin Aspart11$2,996
Levothyroxine Sodium146$1,284
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,088

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$182$134,922107 claims
Novo NordiskOzempic$82$115,36299 claims
Boehringer IngelheimJardiance, Stiolto Respimat$204$50,21264 claims
AstraZenecaFarxiga$18$27,44127 claims
MerckJanuvia$23$11,39116 claims
AbbVieSynthroid$397$4,51782 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$52$1,284146 claims
ANI Pharmaceuticals, Inc.Valsartan$131$42031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,610 family providers in Louisiana.

Other family in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →